Effect of calcium-modifying drugs on glutamate dehydrogenase and isocitrate dehydrogenase activity.
Fox
R
R
School of Pharmacology, Sunderland Polytechnic, U.K.
Markham
A
A
Morgan
R
R
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D004110:Diltiazem / Q000494:pharmacology; D005969:Glutamate Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006706:Homeostasis / Q000187:drug effects; D066298:In Vitro Techniques; D007521:Isocitrate Dehydrogenase / Q000378:metabolism*; D007700:Kinetics; D008929:Mitochondria, Heart / Q000201:enzymology; D051381:Rats; D014700:Verapamil / Q000494:pharmacology
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D014700:Verapamil; D007521:Isocitrate Dehydrogenase; D005969:Glutamate Dehydrogenase; D004110:Diltiazem; D002118:Calcium